Baugh J A, Bucala R
Picower Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA.
Curr Opin Drug Discov Devel. 2001 Sep;4(5):635-50.
The development of tumor necrosis factor-alpha (TNF alpha) inhibitors has been one of the most active areas of drug development over the last ten years for the treatment of inflammatory diseases. Following the definition of TNF alpha as a key mediator of inflammatory disease and the success demonstrated by various anti-TNF alpha strategies in the treatment of rheumatoid arthritis and inflammatory bowel disease, many investigators have sought to refine mechanisms by which to modulate TNF alpha in vivo. Many advances are presently being made in the understanding of how TNF alpha production is regulated, and with this knowledge comes the identification of new targets and pathways for therapeutic intervention. Here, we review the development of the currently available therapeutics and the progressive steps that are being made to improve clinical efficacy of anti-TNF alpha strategies.
在过去十年中，肿瘤坏死因子-α（TNFα）抑制剂的研发一直是治疗炎症性疾病药物研发中最活跃的领域之一。在将TNFα定义为炎症性疾病的关键介质，以及各种抗TNFα策略在类风湿性关节炎和炎症性肠病治疗中取得成功之后，许多研究人员试图完善体内调节TNFα的机制。目前，在理解TNFα产生如何被调节方面取得了许多进展，随着这一知识的出现，也确定了新的治疗干预靶点和途径。在此，我们综述了目前可用疗法的研发情况以及为提高抗TNFα策略的临床疗效而正在采取的逐步措施。
